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with a signiﬁcantmisclassiﬁcationof some species/antifungal com-
binations. In conclusion, historical data needs to be re-evaluated
according to the new breakpoints, in order to make meaningful
conclusions regarding the emergenceof resistance. Regular surveil-
lance studies tracking both the distribution aswell as susceptibility
patterns of Candida species to antifungal agents will provide guid-
ance to clinicians regarding empirical therapy.
http://dx.doi.org/10.1016/j.ijid.2014.03.495
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Candida spp. is an important cause of bloodstream infection
with high morbidity and mortality rate. The growing incidence
is usually related to the complexity of medical and surgical pro-
cedures in the critically-ill patient however, a recent three-year
survey conducted in Italy and Spain, clearly showed that the over-
all incidence was 1.55 cases per 1000 admissions, C. albicans was
the leading agent of infection (58,4%), and the majority of can-
didemia episodes were found in the internal medicine department
(49.6%), followed by the surgical ward, the ICU and the hemato-
oncology ward. The 30-days mortality rate was around 30%. The
higher rate of candidemia is therefore documented in the internal
medicine ward were non critically-ill patients are cared for. Apart
from lenght of hospital stay, broad-spectrum antibiotics and CVC,
risk factors for candidemiamaybe subtle and adelay in appropriate
diagnosis, especially when the blood culture results are negative,
mayrepresenta severe limiting factor in startinga timelyantifungal
therapy. One should take in account that non albicans Candida are
increasingly documented (C. parapsilosis 19.5%, C. tropicalis 9.3%,
C.glabrata 8.3%) and that around 5% of all tested isolates (n =955)
were resistant or susceptible dose dependent (SDD) to ﬂuconazole.
There are several reasons for considering an echinocandin in place
of ﬂuconazole for treating candidemia also in the non critically-
ill patients: broad spectrum of activity including C. krusei and C.
glabrata, fungicidal activity, anti-bioﬁlm activity, a reliable PK/PD
proﬁle, a good safety proﬁle, low rate of drug-drug interactions,
limited need for drug modiﬁcations in case of renal or liver fail-
ure, the burden of clinical evidence from clinical trials. However,
one should also consider the lower microbiological activity “in
vitro” against C. parapsilosis, the growingdocumentationof emerg-
ing resistance related to heavy use or abuse of echinocandins and
ﬁnally the cost. In summary, to be effective, antifungal therapy
should be timely (early start), appropriate (the right drug to the
right patient) and adequate (in terms of dose). Optimal antifungal
therapy should be offered to any patient with suspected or docu-
mented candidemia, including the non critcally-ill patient cared for
in the internal medicine departement.
http://dx.doi.org/10.1016/j.ijid.2014.03.496
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The risk of infection increases with the length of stay in the
intensive care unit (ICU). Invasive fungal infections (IFI) are now
responsible for a sizeable proportion of ICU infections. Candida spp.
are a particular problem in the ICU, where they are not only among
the most common pathogens responsible for blood stream infec-
tions (BSI), but also associated with an unexpectedly high rate of
mortality. Central venous catheters, total parenteral nutrition, and
increasingly, surgery, are common sources of Candida BSI. While
C. albicans remains the most common species implicated in can-
didemia, C. glabrata, C. parapsilosis, C. tropicalis, C. krusei, andother
non-albicans species are often responsible for infection, especially
among older patients (e.g., > 60 years). Risk scores and prediction
rules for Candida BSI are helpful, but not straightforward to apply.
There is also uncertainty around the appropriate length of therapy
for deep-seated Candida infections (e. g., intra-abdominal infec-
tions). Despite predictive, diagnostic, and treatment uncertainties,
correct assessment of patient risk factors for nosocomial Candida
infection is crucial to avoiding the poor outcomes associated with
delayed or inappropriate initial therapy. The reality is that many
ICU patients with Candida IFI are treated late or with ﬂuconazole
despite guidelines that an echinocandin be used as initial ther-
apy for critically ill patients. Furthermore, not all echinocandins
are equally effective, particularly when it comes to non-albicans
Candida infections. The problem of antifungal agents not being
interchangeable extends to treatment of invasive aspergillosis,
where selecting an agent such as voriconazole gives rise to con-
cerns about drug interactions and the need for therapeutic drug
monitoring. Given the increasing problem of candidemia in the ICU
and the shift to non-albicans species, especially in older patients,
early empiric therapy with an echinocandin is essential, as is con-
sideration of surgical co-intervention when urgent measures are
needed. Early empiric therapy with the appropriate echinocandin
and source control are the cornerstones of effective treatment for
Candida BSI.
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